SC development kits: still failing to deliver on promises?

Enhancing endocrine response with novel

Enhancing endocrine response with novel targeted therapies : Why have the clinical trials to date failed to deliver on the preclinical promise?

✍ Stephen R. D. Johnston; Alexandra Leary; Lesley-Ann Martin; Ian E. Smith; Mitch 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

Acquired resistance to endocrine therapies has severely limited their long-term effectiveness in breast cancer. In recent years a clear rationale has developed for combining signal transduction inhibitors (STIs) with endocrine therapies to delay the emergence of acquired resistance and enhance endoc